303 related articles for article (PubMed ID: 24486700)
1. Pentyl-4-yn-VPA, a histone deacetylase inhibitor, ameliorates deficits in social behavior and cognition in a rodent model of autism spectrum disorders.
Foley AG; Cassidy AW; Regan CM
Eur J Pharmacol; 2014 Mar; 727():80-6. PubMed ID: 24486700
[TBL] [Abstract][Full Text] [Related]
2. Class I histone deacetylase inhibition ameliorates social cognition and cell adhesion molecule plasticity deficits in a rodent model of autism spectrum disorder.
Foley AG; Gannon S; Rombach-Mullan N; Prendergast A; Barry C; Cassidy AW; Regan CM
Neuropharmacology; 2012 Sep; 63(4):750-60. PubMed ID: 22683514
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of histone deacetylase in utero causes sociability deficits in postnatal mice.
Moldrich RX; Leanage G; She D; Dolan-Evans E; Nelson M; Reza N; Reutens DC
Behav Brain Res; 2013 Nov; 257():253-64. PubMed ID: 24103642
[TBL] [Abstract][Full Text] [Related]
4. Differential enantioselective effects of pentyl-4-yn-valproate on spatial learning in the rat, and neurite outgrowth and cyclin D3 expression in vitro.
O'Loinsigh ED; Gherardini LM; Gallagher HC; Foley AG; Murphy KJ; Regan CM
J Neurochem; 2004 Jan; 88(2):370-9. PubMed ID: 14690525
[TBL] [Abstract][Full Text] [Related]
5. Chronic treatment with valproic acid or sodium butyrate attenuates novel object recognition deficits and hippocampal dendritic spine loss in a mouse model of autism.
Takuma K; Hara Y; Kataoka S; Kawanai T; Maeda Y; Watanabe R; Takano E; Hayata-Takano A; Hashimoto H; Ago Y; Matsuda T
Pharmacol Biochem Behav; 2014 Nov; 126():43-9. PubMed ID: 25240644
[TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide hydroxamic acid, a novel histone deacetylase inhibitor, improves the development and acetylation level of miniature porcine handmade cloning embryos.
Sun JM; Cui KQ; Li ZP; Lu XR; Xu ZF; Liu QY; Huang B; Shi DS
Reprod Domest Anim; 2017 Oct; 52(5):763-774. PubMed ID: 28432707
[TBL] [Abstract][Full Text] [Related]
7. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
[TBL] [Abstract][Full Text] [Related]
8. Pentyl-4-yn-valproic acid enhances both spatial and avoidance learning, and attenuates age-related NCAM-mediated neuroplastic decline within the rat medial temporal lobe.
Murphy KJ; Fox GB; Foley AG; Gallagher HC; O'Connell A; Griffin AM; Nau H; Regan CM
J Neurochem; 2001 Aug; 78(4):704-14. PubMed ID: 11520891
[TBL] [Abstract][Full Text] [Related]
9. Pentyl-4-yn-valproic acid reverses age-associated memory impairment in the Wistar rat.
Foley AG; Gallagher HC; Murphy KJ; Regan CM
Neurobiol Aging; 2004 Apr; 25(4):539-46. PubMed ID: 15013575
[TBL] [Abstract][Full Text] [Related]
10. Gender-specific behavioral and immunological alterations in an animal model of autism induced by prenatal exposure to valproic acid.
Schneider T; Roman A; Basta-Kaim A; Kubera M; Budziszewska B; Schneider K; Przewłocki R
Psychoneuroendocrinology; 2008 Jul; 33(6):728-40. PubMed ID: 18396377
[TBL] [Abstract][Full Text] [Related]
11. Male-specific alteration in excitatory post-synaptic development and social interaction in pre-natal valproic acid exposure model of autism spectrum disorder.
Kim KC; Kim P; Go HS; Choi CS; Park JH; Kim HJ; Jeon SJ; Dela Pena IC; Han SH; Cheong JH; Ryu JH; Shin CY
J Neurochem; 2013 Mar; 124(6):832-43. PubMed ID: 23311691
[TBL] [Abstract][Full Text] [Related]
12. Animal model of autism induced by prenatal exposure to valproate: behavioral changes and liver parameters.
Bambini-Junior V; Rodrigues L; Behr GA; Moreira JC; Riesgo R; Gottfried C
Brain Res; 2011 Aug; 1408():8-16. PubMed ID: 21767826
[TBL] [Abstract][Full Text] [Related]
13. Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid.
Kataoka S; Takuma K; Hara Y; Maeda Y; Ago Y; Matsuda T
Int J Neuropsychopharmacol; 2013 Feb; 16(1):91-103. PubMed ID: 22093185
[TBL] [Abstract][Full Text] [Related]
14. The ketogenic diet modifies social and metabolic alterations identified in the prenatal valproic acid model of autism spectrum disorder.
Ahn Y; Narous M; Tobias R; Rho JM; Mychasiuk R
Dev Neurosci; 2014; 36(5):371-80. PubMed ID: 25011527
[TBL] [Abstract][Full Text] [Related]
15. Rearrangement of the dendritic morphology in limbic regions and altered exploratory behavior in a rat model of autism spectrum disorder.
Bringas ME; Carvajal-Flores FN; López-Ramírez TA; Atzori M; Flores G
Neuroscience; 2013 Jun; 241():170-87. PubMed ID: 23535253
[TBL] [Abstract][Full Text] [Related]
16. S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides.
Eikel D; Hoffmann K; Zoll K; Lampen A; Nau H
Drug Metab Dispos; 2006 Apr; 34(4):612-20. PubMed ID: 16415118
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic evidence of an Ac/Dc axis by VPA and SAHA.
Lunke S; Maxwell S; Khurana I; K N H; Okabe J; Al-Hasani K; El-Osta A
Clin Epigenetics; 2021 Mar; 13(1):58. PubMed ID: 33743782
[TBL] [Abstract][Full Text] [Related]
18. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
19. Hepatoprotection and lethality rescue by histone deacetylase inhibitor valproic acid in fatal hemorrhagic shock.
Gonzales ER; Chen H; Munuve RM; Mehrani T; Nadel A; Koustova E
J Trauma; 2008 Sep; 65(3):554-65. PubMed ID: 18784568
[TBL] [Abstract][Full Text] [Related]
20. Multiple effects of pentyl-4-yn-VPA enantiomers: from toxicity to short-term memory enhancement.
Gotfryd K; Owczarek S; Hoffmann K; Klementiev B; Nau H; Berezin V; Bock E; Walmod PS
Neuropharmacology; 2007 Mar; 52(3):764-78. PubMed ID: 17095022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
